Predict your next investment

Corporation
ipsen.com

See what CB Insights has to offer

Investments

9

Portfolio Exits

2

Partners & Customers

10

Service Providers

1

About Ipsen Group

Ipsen is a pharmaceutical group that provides specialty healthcare solutions for targeted, debilitating diseases. Its fields of expertise cover oncology, neurosciences, and endocrinology. Ipsen's portfolio of key therapies improves the care of patients suffering from neuro-endocrine tumors, prostate cancer, bladder cancer, and renal cancer. Ipsen also has a significant presence in primary care.

Ipsen Group Headquarter Location

65, quai Georges Gorse

Boulogne-Billancourt, 92100,

France

+33 (0)1 58 33 50 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ipsen Group

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Ipsen Group in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Ipsen Group News

Ipsen is casting a wider BD net under new CEO Loew

Dec 13, 2020

Biocentury French pharma to use $3B war chest to add clinical candidates, late-stage U.S. program The French pharma is stepping up its pursuit of external innovation to fill out its pipeline with NMEs ahead of generic competition for its best-selling drug. By stephen hansen, associate editor Dec 12, 2020 | 4:16 PM GMT With a pipeline heavy on line extensions and its bestseller headed toward a patent cliff, new Ipsen CEO David Loew is doubling down on the mid-cap biopharma’s commitment to external innovation. But this time, Ipsen will be looking for programs across a broader range of indications and with a focus on mid-sized, rather than blockbuster, opportunities. Tipping the scales towards external innovation isn’t a new idea for Ipsen Group (Euronext:IPN). In 2017, then CEO David Meek had set a course for Ipsen to  fill out its clinical pipeline  through BD Read the full 1469 word article User Sign In Sign in

Ipsen Group Investments

9 Investments

Ipsen Group has made 9 investments. Their latest investment was in Pyxis Oncology as part of their Series B on March 3, 2021.

CBI Logo

Ipsen Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/30/2021

Series B

Pyxis Oncology

$152M

No

Acuta Capital, Arix Bioscience, BVF Partners, Cormorant Asset Management, HBM Healthcare Investments, Janus Henderson Investors, Laurion Capital Management, Leaps by Bayer, LifeSci Venture Partners, Logos Capital, Longwood Fund, Perceptive Advisors, Pfizer Venture Investments, RA Capital Management, Ridgeback Capital Management, RTW Investments, Surveyor Capital, Tekla Capital Management, and Undisclosed Investors

2

3/2/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

7/12/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

2/16/2017

Mezzanine

Subscribe to see more

$99M

Subscribe to see more

10

1/31/2017

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/30/2021

3/2/2020

7/12/2019

2/16/2017

1/31/2017

Round

Series B

Series B

Series A

Mezzanine

Corporate Minority

Company

Pyxis Oncology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$152M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Acuta Capital, Arix Bioscience, BVF Partners, Cormorant Asset Management, HBM Healthcare Investments, Janus Henderson Investors, Laurion Capital Management, Leaps by Bayer, LifeSci Venture Partners, Logos Capital, Longwood Fund, Perceptive Advisors, Pfizer Venture Investments, RA Capital Management, Ridgeback Capital Management, RTW Investments, Surveyor Capital, Tekla Capital Management, and Undisclosed Investors

Sources

2

10

10

10

10

Ipsen Group Portfolio Exits

2 Portfolio Exits

Ipsen Group has 2 portfolio exits. Their latest portfolio exit was Rhythm Pharmaceuticals on October 05, 2017.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/5/2017

IPO

$991

6

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

10/5/2017

00/00/0000

Exit

IPO

Subscribe to see more

Companies

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Sources

6

10

Ipsen Group Acquisitions

8 Acquisitions

Ipsen Group acquired 8 companies. Their latest acquisition was Clementia Pharmaceuticals on April 18, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

4/18/2019

IPO

$991

$92.5M

Acq - P2P

7

2/13/2017

Subscribe to see more

$991

$99M

Subscribe to see more

10

1/8/2017

Subscribe to see more

$99M

Subscribe to see more

10

5/19/2015

Series A

Subscribe to see more

$991

$99M

Subscribe to see more

10

2/24/2015

Grant

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

4/18/2019

2/13/2017

1/8/2017

5/19/2015

2/24/2015

Investment Stage

IPO

Series A

Grant

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Total Funding

$92.5M

$99M

$99M

$99M

$99M

Note

Acq - P2P

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

7

10

10

10

10

Ipsen Group Partners & Customers

10 Partners and customers

Ipsen Group has 10 strategic partners and customers. Ipsen Group recently partnered with Exicure on August 8, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

8/2/2021

Licensor

Exicure

United States

Ipsen And Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders

Ipsen and Exicure , Inc. Inc. - Get Report have signed an exclusive collaboration agreement to research , develop , and commercialize novel Spherical Nucleic Acids as potential investigational treatments for Huntington Study Group 's disease and Angelman syndrome .

6

8/2/2021

Partner

Exicure

United States

Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders - Ipsen

Ipsen and Exicure , Inc. enter into exclusive collaboration targeting rare neurodegenerative disorders .

1

7/15/2021

Licensor

IRLAB Therapeutics

Sweden

Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease

The agreement and partnership with Ipsen is a validation of our proprietary discovery platform , ISP , and our drug development efforts .

4

3/31/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

2/9/2021

Vendor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/2/2021

8/2/2021

7/15/2021

3/31/2021

2/9/2021

Type

Licensor

Partner

Licensor

Partner

Vendor

Business Partner

Exicure

Exicure

IRLAB Therapeutics

Country

United States

United States

Sweden

Subscribe to see more

Subscribe to see more

News Snippet

Ipsen And Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders

Ipsen and Exicure , Inc. Inc. - Get Report have signed an exclusive collaboration agreement to research , develop , and commercialize novel Spherical Nucleic Acids as potential investigational treatments for Huntington Study Group 's disease and Angelman syndrome .

Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders - Ipsen

Ipsen and Exicure , Inc. enter into exclusive collaboration targeting rare neurodegenerative disorders .

Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease

The agreement and partnership with Ipsen is a validation of our proprietary discovery platform , ISP , and our drug development efforts .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

6

1

4

10

10

Ipsen Group Service Providers

1 Service Provider

Ipsen Group has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acquired

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Ipsen Group Team

3 Team Members

Ipsen Group has 3 team members, including former Senior Vice President, Véronique Riethuisen.

Name

Work History

Title

Status

Véronique Riethuisen

Senior Vice President

Former

Karen Zinkewich-Péotti

Senior Vice President

Former

Andrew Scully

Senior Director

Former

Name

Véronique Riethuisen

Karen Zinkewich-Péotti

Andrew Scully

Work History

Title

Senior Vice President

Senior Vice President

Senior Director

Status

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.